Cancer Genetics Launches Revolutionary Weapon For The War On Cancer
10/19/2005 5:09:26 PM
At the American Society of Hematology meeting today in San Diego, CA, Cancer Genetics, Inc. (CGI) launched a new, highly sensitive, DNA FISH assay to help diagnose and monitor therapy of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). This assay is the first "repeat-free" BCR/ABL four color fluorescent in situ hybridization (F-FISH) probe and is CGI’s first product to be introduced into the United States.
comments powered by